Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia

被引：104

作者：

Huang, Xiao-Jun ^{[1
]}

Liu, Dai-Hong ^{[1
]}

Liu, Kai-Yan ^{[1
]}

Xu, Lan-Ping ^{[1
]}

Chen, Yu-Hong ^{[1
]}

Wang, Yu ^{[1
]}

Han, Wei ^{[1
]}

Chen, Huan ^{[1
]}

机构：

[1] Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2008年 / 28卷 / 03期

关键词：

donor lymphocyte infusion; HLA-mismatched; transplantation; haploidentical; HSCT; GVHD; relapse; DLI;

D O I：

10.1007/s10875-007-9166-z

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

We evaluated the safety and efficacy of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor priming and short-term immumosuppressive agents for prophylaxis of relapse in patients with advanced leukemia after human leukocyte antigen (HLA)-mismatched T cell-replete hematopoietic stem cell transplantation (HCT). Twenty-nine patients received prophylactic DLI at a median 75 (33-120) days after HCT. Acute graft-vs-host disease (GVHD) grades 3-4 occurred in six patients, and all cases were controlled. Eleven patients were alive and relapse-free with a probability of leukemia-free survival (LFS) of 37.3 +/- 9.6% at 3 years. Chronic GVHD was associated with a lower relapse rate and higher probability of LFS. Prophylactic-modified DLI is feasible in patients with advanced leukemia to prevent relapse after HLA-mismatched HCT.

引用

页码：276 / 283

页数：8

共 26 条

[1]

Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation [J].